Acelrx Pharmaceuticals Inc Valor contable por acción
¿Qué es el Valor contable por acción de Acelrx Pharmaceuticals Inc?
El Valor contable por acción de Acelrx Pharmaceuticals Inc es 0.08
¿Cuál es la definición de Valor contable por acción?
El valor en libros por acción es el activo de una empresa menos el pasivo dividido por el número de acciones en circulación.
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Valor contable por acción de compañías en Sector Health Care en NASDAQ en comparadas con Acelrx Pharmaceuticals Inc
¿Qué hace Acelrx Pharmaceuticals Inc?
acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and v
Empresas con valor contable por acción similar a Acelrx Pharmaceuticals Inc
- Stampede Capital tiene Valor contable por acción de 0.08
- Twintek Investment tiene Valor contable por acción de 0.08
- Alloy Resources tiene Valor contable por acción de 0.08
- New Oroperu Resources tiene Valor contable por acción de 0.08
- Spartan Acquisition tiene Valor contable por acción de 0.08
- Labrador Gold tiene Valor contable por acción de 0.08
- Acelrx Pharmaceuticals Inc tiene Valor contable por acción de 0.08
- American Rare Earths tiene Valor contable por acción de 0.08
- 5G Networks tiene Valor contable por acción de 0.08
- Visioneering Technologies tiene Valor contable por acción de 0.08
- Loco Hong Kong tiene Valor contable por acción de 0.08
- Four Arrows Capital tiene Valor contable por acción de 0.08
- Sintana tiene Valor contable por acción de 0.08